Compare Crispr Therapeutics AG (CRSP) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.

The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.

Liberty Global (LBTYK) trades at $8.75, down 1.91% amid bearish technical signals and mixed earnings performance. The stock shows attractive valuation metrics with P/S of 0.61 and P/B of 0.32, but fundamental challenges persist with negative net income margin of -62.14% and ROE of -27.32%. Recent developments include strategic AI partnerships and progress toward Ziggo Group's planned 2027 listing, providing potential catalysts.

While analyst consensus remains bullish with 69% buy ratings and $12.67 price target, investors face significant execution risks amid ongoing losses. The company's cash position and asset monetization strategy provide downside support, but profitability improvement is crucial for sustained recovery. Current levels may offer value for patient investors betting on management's restructuring efforts.